These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33767454)

  • 1. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
    [No Abstract]   [Full Text] [Related]  

  • 2. US Food and Drug Administration approval overview in metastatic breast cancer.
    Cortazar P; Justice R; Johnson J; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2012 May; 30(14):1705-11. PubMed ID: 22430273
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 4. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
    DeLoughery EP; Prasad V
    Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibody approved for metastatic breast cancer.
    Oncology (Williston Park); 1998 Dec; 12(12):1727. PubMed ID: 9874846
    [No Abstract]   [Full Text] [Related]  

  • 6. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing end points in breast-cancer drug approval--the Avastin story.
    D'Agostino RB
    N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncology 2020: a drug development and approval paradigm.
    Dhingra K
    Ann Oncol; 2015 Nov; 26(11):2347-50. PubMed ID: 26374285
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avastin hearing leads to more uncertainty over drug's future.
    Goozner M
    J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
    [No Abstract]   [Full Text] [Related]  

  • 12. Can cancer clinical trials be fixed?
    Allison M
    Nat Biotechnol; 2011 Jan; 29(1):13-5. PubMed ID: 21221090
    [No Abstract]   [Full Text] [Related]  

  • 13. Reputation and precedent in the bevacizumab decision.
    Carpenter D; Kesselheim AS; Joffe S
    N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
    Green DJ; Sun H; Burnham J; Liu XI; van den Anker J; Temeck J; Yao L; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2019 Mar; 105(3):555-557. PubMed ID: 30094815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inappropriate use of progression-free survival in cancer drug approvals.
    Naci H; Davis C
    BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
    [No Abstract]   [Full Text] [Related]  

  • 17. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.
    Berry DA; Hudis CA
    JAMA Oncol; 2015 Oct; 1(7):875-6. PubMed ID: 26181139
    [No Abstract]   [Full Text] [Related]  

  • 19. "Dangling" Accelerated Approvals in Oncology.
    Beaver JA; Pazdur R
    N Engl J Med; 2021 May; 384(18):e68. PubMed ID: 33882220
    [No Abstract]   [Full Text] [Related]  

  • 20. Off-label uses of bevacizumab: breast and lung cancer indications.
    Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.